Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-020 - Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)

      Presenter: David Spigel

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-070 - High Incidence of Peridiagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer

      Presenter: Inmaculada Aparicio Salcedo

      • Abstract

      Loading...

    • +

      EP08.02-131 - Alectinib after Crizotinib Failure in Patients with Advanced ALK‑Positive NSCLC: Results from the Spanish Early Access Program

      Presenter: Reyes Bernabé-Caro

      • Abstract

      Loading...

  • +

    P1.11 - Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
    • +

      P1.11-01 - Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung

      Presenter: Hye Ryun Kim

      • Abstract

      Loading...

  • +

    OA07 - Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?

    • 11:00 - 12:00
    • 8/08/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
    • +

      Session Moderator

      11:22 - 11:32  |  Presenter: Lubos Petruzelka

      • Abstract

      Loading...

    • +

      Session Moderator

      11:22 - 11:32  |  Presenter: Pilar Garrido

      • Abstract

      Loading...

    • +

      OA07.01 - Session Introduction

      11:00 - 11:01  |  Presenter: Lubos Petruzelka

      • Abstract

      Loading...

    • +

      OA07.02 - Session Introduction

      11:01 - 11:02  |  Presenter: Pilar Garrido

      • Abstract

      Loading...

    • +

      OA07.03 - Association Between Genetic Variation in the ATP-binding Cassette Transporter ABCC10 and nab-PTX Treatment in Japanese Cohort

      11:02 - 11:12  |  Presenter: Minoru Horiuchi

      • Abstract

      Loading...

    • +

      OA07.04 - Overall Survival in Patients With Advanced NSCLC Receiving Taxane-Containing Regimen After Exposure to Immunotherapy and Platinum-Doublet

      11:12 - 11:22  |  Presenter: Stephen V. Liu

      • Abstract

      Loading...

    • +

      OA07.05 - Gemcitabine Plus Platinum Chemotherapy Re-challenge in Metastatic Pulmonary Lymphoepithelioma-like Carcinoma

      11:22 - 11:32  |  Presenter: Gavin Tin Chun Cheung

      • Abstract

      Loading...

    • +

      OA07.06 - Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)

      11:32 - 11:42  |  Presenter: Edouard Auclin

      • Abstract

      Loading...

    • +

      OA07.07 - Discussant

      11:42 - 11:52  |  Presenter: Navneet Singh

      • Abstract

      Loading...

    • +

      OA07.08 - Live Q&A

      11:52 - 12:00

      • Abstract

      Loading...

  • +

    P2.07 - Pathology - Tumour Genomics

    • 17:15 - 19:15
    • 8/08/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Pathology - Tumour Genomics
    • +

      P2.07-02 - RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

      Presenter: Susana Hernandez

      • Abstract

      Loading...

  • +

    OA15 - Patient Selection in Advanced NSCLC Immunotherapy

    • 14:30 - 15:30
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      Session Moderator

      14:32 - 00:00  |  Presenter: Pilar Garrido

      • Abstract

      Loading...

    • +

      Session Moderator

      14:32 - 00:00  |  Presenter: António Araújo

      • Abstract

      Loading...

    • +

      OA15.01 - Session Introduction

      14:30 - 14:31  |  Presenter: Pilar Garrido

      • Abstract

      Loading...

    • +

      OA15.02 - Session Introduction

      14:31 - 14:32  |  Presenter: António Araújo

      • Abstract

      Loading...

    • +

      OA15.03 - Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100

      14:32 - 14:42  |  Presenter: Martin Reck

      • Abstract

      Loading...

    • +

      OA15.04 - Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC

      14:42 - 14:52  |  Presenter: Solange Peters

      • Abstract

      Loading...

    • +

      OA15.05 - HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy

      14:52 - 15:02  |  Presenter: Benjamin Besse

      • Abstract

      Loading...

    • +

      OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer

      15:02 - 15:12  |  Presenter: Delvys Rodriguez-Abreu

      • Abstract

      Loading...

    • +

      OA15.07 - Discussant

      15:12 - 15:22  |  Presenter: Puey Ling Chia

      • Abstract

      Loading...

    • +

      OA15.08 - Live Q&A

      15:22 - 15:30

      • Abstract

      Loading...